S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis
出版年份 2013 全文链接
标题
S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis
作者
关键词
-
出版物
BRITISH JOURNAL OF CANCER
Volume 109, Issue 6, Pages 1420-1427
出版商
Springer Nature
发表日期
2013-08-21
DOI
10.1038/bjc.2013.479
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial
- (2012) Yong Sang Hong et al. LANCET ONCOLOGY
- Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2009
- (2012) Kyu-Won Jung et al. Cancer Research and Treatment
- CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients
- (2011) S R Park et al. BRITISH JOURNAL OF CANCER
- Durable Complete Responses in Metastatic Colorectal Cancer Treated with Chemotherapy Alone
- (2011) Renata Ferrarotto et al. Clinical Colorectal Cancer
- Phase II study of a triplet regimen of S-1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: clinical and pharmacogenetic results
- (2010) S. R. Park et al. ANNALS OF ONCOLOGY
- Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients
- (2010) Benjamin Chuah et al. CANCER SCIENCE
- Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial
- (2010) Gianluca Masi et al. LANCET ONCOLOGY
- Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study)
- (2010) Kei Muro et al. LANCET ONCOLOGY
- Long-Term Outcome of Initially Unresectable Metastatic Colorectal Cancer Patients Treated with 5-Fluorouracil/Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Followed by Radical Surgery of Metastases
- (2009) Gianluca Masi et al. ANNALS OF SURGERY
- A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer
- (2009) E Vasile et al. BRITISH JOURNAL OF CANCER
- Cancer Pharmacoethnicity: Ethnic Differences in Susceptibility to the Effects of Chemotherapy
- (2009) P. H. O'Donnell et al. CLINICAL CANCER RESEARCH
- Predictive Role of the UGT1A1, UGT1A7, and UGT1A9 Genetic Variants and Their Haplotypes on the Outcome of Metastatic Colorectal Cancer Patients Treated With Fluorouracil, Leucovorin, and Irinotecan
- (2009) Erika Cecchin et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- (2009) Eric Van Cutsem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association ofCYP2A6polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer
- (2009) Sun-Young Kong et al. PHARMACOGENOMICS
- A phase II study of S-1 plus irinotecan and oxaliplatin in heavily-treated patients with metastatic colorectal cancer
- (2008) Sun Young Kim et al. INVESTIGATIONAL NEW DRUGS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search